PAVmed Inc.

PAVM Nasdaq CIK: 0001624326

Company Information

Industry Surgical & Medical Instruments & Apparatus
SIC Code 3841
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 360 MADISON AVENUE, NEW YORK, NY, 10017
Mailing Address 360 MADISON AVENUE, NEW YORK, NY, 10017
Phone (212) 949-4319
Fiscal Year End 1231
EIN 471214177

Financial Overview

FY2025

Recent SEC Filings

Form Type Date Filed Document
3 Initial insider ownership report April 6, 2026 View on SEC
4 Insider stock transaction report April 3, 2026 View on SEC
4 Insider stock transaction report April 3, 2026 View on SEC
4 Insider stock transaction report April 3, 2026 View on SEC
4 Insider stock transaction report April 3, 2026 View on SEC
4 Insider stock transaction report April 3, 2026 View on SEC
4 Insider stock transaction report April 3, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) April 3, 2026 View on SEC
4 Insider stock transaction report April 3, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment April 3, 2026 View on SEC

Annual Reports

10-K March 27, 2026
  • Significant revenue growth from $0.7 million to $2.8 million year-over-year
  • Majority ownership of Lucid Diagnostics, a high-potential medical tech subsidiary
View Analysis

Material Events

8-K Other January 23, 2026
High Impact
  • PAVmed Inc. has successfully regained full compliance with Nasdaq's listing requirements.
  • This resolution removes the risk of delisting, protecting shareholder value and maintaining stock accessibility.
View Analysis
8-K Financial Distress December 30, 2025
High Impact
  • PAVmed Inc. announced a 1-for-30 reverse stock split.
  • The company is also significantly reducing its total authorized shares from 250 million to 25 million.
View Analysis
8-K Strategy Change December 5, 2025
High Impact
  • PAVmed stockholders approved a reverse stock split and a significant reduction in the total number of authorized shares.
  • The board of directors now has the power to implement a reverse stock split with a ratio between 1-for-10 and 1-for-30.
View Analysis

Related Companies

Companies in the same industry (SIC: 3841)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.